SG Americas Securities LLC bought a new stake in shares of Anika Therapeutics Inc (NASDAQ:ANIK) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 6,528 shares of the biotechnology company’s stock, valued at approximately $209,000.
Other institutional investors have also added to or reduced their stakes in the company. Piedmont Investment Advisors LLC acquired a new position in Anika Therapeutics during the 2nd quarter valued at about $110,000. American Century Companies Inc. acquired a new position in Anika Therapeutics during the 1st quarter valued at about $247,000. First Trust Advisors LP acquired a new position in Anika Therapeutics during the 2nd quarter valued at about $250,000. HL Financial Services LLC lifted its position in Anika Therapeutics by 35.5% during the 2nd quarter. HL Financial Services LLC now owns 7,900 shares of the biotechnology company’s stock valued at $253,000 after purchasing an additional 2,071 shares during the period. Finally, WINTON GROUP Ltd acquired a new position in Anika Therapeutics during the 1st quarter valued at about $401,000. Institutional investors own 94.81% of the company’s stock.
A number of research analysts have issued reports on the stock. ValuEngine downgraded shares of Anika Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, June 21st. BidaskClub upgraded shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 4th. Zacks Investment Research downgraded shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 17th. Barrington Research upgraded shares of Anika Therapeutics from a “market perform” rating to an “outperform” rating and set a $48.00 target price on the stock in a research report on Friday, July 27th. Finally, First Analysis downgraded shares of Anika Therapeutics from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $45.00 to $34.00 in a research report on Wednesday, June 20th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $43.00.
Shares of NASDAQ:ANIK opened at $42.06 on Thursday. The company has a market capitalization of $618.93 million, a P/E ratio of 26.04, a PEG ratio of 2.74 and a beta of 2.04. Anika Therapeutics Inc has a fifty-two week low of $28.54 and a fifty-two week high of $69.81.
Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings results on Wednesday, July 25th. The biotechnology company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.39. The business had revenue of $30.55 million for the quarter, compared to the consensus estimate of $27.47 million. Anika Therapeutics had a net margin of 16.94% and a return on equity of 9.53%. Anika Therapeutics’s revenue for the quarter was down 8.7% on a year-over-year basis. During the same period last year, the company posted $0.76 EPS. research analysts predict that Anika Therapeutics Inc will post 1.55 earnings per share for the current fiscal year.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.
Featured Story: Price to Earnings Ratio (PE), For Valuing Stocks
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc (NASDAQ:ANIK).
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.